Chemistry:NIM811
From HandWiki
| |
| Identifiers | |
|---|---|
3D model (JSmol)
|
|
| ChEMBL | |
PubChem CID
|
|
| UNII | |
| |
| Properties | |
| C62H111N11O12 | |
| Molar mass | 1202.61 g/mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
 verify (what is   ?)
| |
| Infobox references | |
Tracking categories (test):
NIM811 is a mitochondrial permeability transition inhibitor. Also known as N-methyl-4-isoleucine cyclosporin, it is a four-substituted cyclosporine analogue that binds to cyclophilin, however this binary complex cannot bind to calcineurin, and therefore lacks immunosuppressive activity.
NIM811 is a form of treatment for patients with the hepatitis C virus (HCV). Studies indicate a strong relationship between a treatments cyclophilin binding affinity and suppression of HCV activity.[1] NIM811 is also being studied as a potential treatment to genetic muscular diseases such as Ullrich congenital muscular dystrophy (UCMD) and Bethlem myopathy (BM) disease, diseases altering the genes for collagen VI production.[2]
References
- ↑ Ma, Sue; Boerner, Joanna E.; TiongYip, ChoiLai; Weidmann, Beat; Ryder, Neil S.; Cooreman, Michael P.; Lin, Kai (2006–2009). "NIM811, a Cyclophilin Inhibitor, Exhibits Potent In Vitro Activity against Hepatitis C Virus Alone or in Combination with Alpha Interferon". Antimicrobial Agents and Chemotherapy 50 (9): 2976–2982. doi:10.1128/AAC.00310-06. ISSN 0066-4804. PMID 16940091.
- ↑ Bernardi, Paolo; Argenton, Francesco; Bonaldo, Paolo; Braghetta, Paola; Sabatelli, Patrizia; Maraldi, Nadir Mario; Merlini, Luciano; Blaauw, Bert et al. (2014-10-15). "NIM811, a cyclophilin inhibitor without immunosuppressive activity, is beneficial in collagen VI congenital muscular dystrophy models" (in en). Human Molecular Genetics 23 (20): 5353–5363. doi:10.1093/hmg/ddu254. ISSN 0964-6906. PMID 24852368.
 |  |
